试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
编号:NCT05451654登记状态:提前终止企业 / 申办者:Medesis Pharma SA
药物 / 成分:Placebo、Experimental drug
登记的停止原因(原文):the number of patients recruited was not reached because covid cases were low
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
A Study to Assess NEU-723 in Healthy Participants
编号:NCT05633745登记状态:提前终止企业 / 申办者:Neuron23 Inc.
药物 / 成分:NEU-723、Placebo
登记的停止原因(原文):Business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-25
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
编号:NCT02385123登记状态:提前终止企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:Influenza Virus Vaccine Inactivated
登记的停止原因(原文):Study was terminated due to COVID-19 pandemic.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-25
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
编号:NCT03733691登记状态:提前终止企业 / 申办者:Oncotherapeutics
药物 / 成分:Ixazomib、Lenalidomide
登记的停止原因(原文):Insufficient enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-25
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
编号:NCT03824808登记状态:提前终止企业 / 申办者:University of Missouri-Columbia
药物 / 成分:Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution、0.9% Sodium Chloride Injection
登记的停止原因(原文):Challenges with recruitment of surgical research subjects in the target population.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-25
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
编号:NCT04843579登记状态:提前终止企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Selinexor、Clarithromycin、Pomalidomide、Dexamethasone
登记的停止原因(原文):low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-25
Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
编号:NCT04890353登记状态:提前终止企业 / 申办者:Xuanwu Hospital, Beijing
药物 / 成分:Dimethyl fumarate
登记的停止原因(原文):The interim analysis of another associated study is not very effective
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-25
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
编号:NCT05255484登记状态:提前终止企业 / 申办者:LaNova Medicines Limited
药物 / 成分:LM-108、An Anti-PD-1 Antibody
登记的停止原因(原文):Completed primary objective.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-24
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
编号:NCT00170950登记状态:提前终止企业 / 申办者:Novartis
药物 / 成分:Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1、Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2、Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter、Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
登记的停止原因(原文):The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-24
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
编号:NCT00736450登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:oblimersen sodium、rituximab、cyclophosphamide、doxorubicin hydrochloride
登记的停止原因(原文):Manufacturer is no longer making the drug.
查看官方原始记录 ↗